Welcome to the CLiC Podcast channel, providing timely and brief podcasts on studies and articles reviewed by CLiC members:

CLiC Podcast Episode #1: Dr. Carolyn Owen reviews the CLL Clinical Trial (6:43)

If you haven’t yet participated in the poll, we invite you to share your views on Chemo-Immunotherapy for CLL:

Excluding patients with del(17p)/TP53 mutation, which patients should be receiving chemo-immunotherapy firstline for CLL today?

• None – every patient should be receiving novel agents firstline today
• Only young, fit with mutated IgVH who are eligible for curative-intent FCR
• All patients except young and fit with unmutated IgHV
• All patients firstline

Click here to answer

We invite you to view the video of the recent (Nov 22, 2018) webinar discussion led by CLiC scientific committee leaders Dr. Carolyn Owen, Dr. Versha Banerji and Dr. Laurie Sehn, reviewing key questions in CLL. Click to view: http://bit.ly/2IiD0K8

CLiC Question #4: How do you transition patients from a BCRi agent to venetoclax? (2 replies to date)

CLiC Question #5: How often should you dose reduce ibrutinib for toxicity? Do you think that lower doses are better tolerated or that dose reductions are unwise? (1 reply to date)

CLiC Question #6: Which patients are appropriate for first-line ibrutinib? (no replies to date)

We invite you to review the CLiC micromodule video titled “A Summary of Discussions Surrounding CLL Treatment”, reviewing the key points of the in-depth discussions held by the CLiC community in the first half of 2018. The video is approximately 10 minutes in length.

Watch the micromodules here:

English: http://bit.ly/2Ii4Xl0

French: http://bit.ly/2MRaeo3

We invite you to view the video of the recent (May 9) webinar discussion led by CLiC scientific committee leaders Dr. Carolyn Owen and Dr. April Shamy, reviewing key questions in CLL. Click to view: http://bit.ly/2WJzZWW

Please join CLiC scientific committee leaders Dr. Carolyn Owen, Dr. Graeme Fraser, and Dr. April Shamy for a webinar Wednesday, May 9, 7:00 pm EST (access info was sent to you by email on April 30) to review the recent online discussion in the CLiC community around the following questions:

• Q1: Would you be willing to change your practice to use VR in first relapse instead of ibrutinib based on the MURANO data? (3 replies to date)
• Q2: In which population should FCR still be considered the standard of care in Canada? (2 repliesto date)
• Q3: Based on currently available data, is chemo-immunotherapy an appropriate option for patients with relapsed CLL or should every patient be treated with targeted therapy at relapse? (1 reply to date)

Webinar connection details were sent to you by email on April 30 – please check your inbox. If you have any questions about the webinar or how to connect, please contact paul.abbass@legitimed.com.

Prior to the webinar, you are invited to visit the CLiC community on Sosido to review the questions & responses and to reply with your personal clinical perspectives